TargetBeta
RPL17
ribosomal protein L17 · also rpL23, L17, uL22 · L ribosomal proteins
1 program in company-led studies act on RPL17, from 1 company: 0 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (1 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| exalurenrule | Eloxx Pharmaceuticals | phase 2 | 91 running | FAU, RPL10, RPL10A, RPL11, RPL12, RPL13, RPL13A, RPL14, RPL15, RPL18, RPL18A, RPL19, RPL21, RPL22, RPL23, RPL23A, RPL24, RPL26, RPL27, RPL27A, RPL28, RPL29, RPL3, RPL30, RPL31, RPL32, RPL34, RPL35, RPL35A, RPL36, RPL36A, RPL37, RPL37A, RPL38, RPL39, RPL4, RPL41, RPL5, RPL6, RPL7, RPL7A, RPL8, RPL9, RPLP0, RPLP1, RPS10, RPS11, RPS12, RPS13, RPS14, RPS15, RPS15A, RPS16, RPS17, RPS18, RPS19, RPS2, RPS20, RPS21, RPS23, RPS24, RPS25, RPS26, RPS27, RPS27A, RPS28, RPS29, RPS3, RPS3A, RPS4X, RPS4Y1, RPS5, RPS6, RPS7, RPS8, RPS9, RPSA | ChEMBL |
Also acted on by the same programs
Conditions their studies are in
- Cystic Fibrosis, 1 program
- Cystinosis, 1 program
- Genetic Diseases, Inborn, 1 program
- Nephritis, Hereditary, 1 program
- Renal Insufficiency, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Jun 30, 2027exaluren · Eloxx Pharmaceuticals · phase 2 · NCT07523581
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.